IL-6/STAT3信号通路与结直肠癌关系的研究进展

被引：28

作者：

田赟

陈红

任常山

机构：

[1] 中国医科大学附属第一医院肿瘤研究所

来源：

中华肿瘤防治杂志 | 2010年 / 17卷 / 06期

关键词：

结直肠肿瘤,IL-6; IL-6/STAT3通路; 综述文献;

D O I：

10.16073/j.cnki.cjcpt.2010.06.023

中图分类号：

R735.3 [肠肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

目的:探讨白细胞介素-6(interleu-kin-6,IL-6)/信号传导子及转录激活子3(signal transducer and activator of transcrip-tion3,STAT3)通路与结直肠癌(colorectalcancer,CRC)关系的研究进展。方法:以CRC和IL-6;CRC和STAT3为关键词,检索1989-2009年PubMed及CNKI期刊全文数据库,分别检索到英文文献438和76篇及中文文献1 824和391篇。检索到纳入标准:1)IL-6/STAT3通路与CRC发病机制相关文献;2)IL-6/STAT3通路与CRC诊疗相关研究。粗选有96篇关于IL-6/STAT3通路与CRC关系的研究文章,根据纳入标准精选33篇文献纳入。结果:IL-6是一种多效细胞因子。研究证实,IL-6在肿瘤患者外周血和肿瘤组织中均呈现高表达。IL-6与其相应受体结合,受体复合物结合gp130后活化STAT3。近年研究发现CRC中存在STAT3过度活化和功能紊乱现象。IL-6和STAT3的变化最终诱导IL-6/STAT3通路下游与炎症、癌症密切相关分子的表达。结论:对IL-6/STAT3通路的深入研究,为揭示CRC发病机制提供新的思路,为研发针对此通路治疗CRC的特异性药物提供了理论基础。

引用

页码：475 / 478

页数：4

共 14 条

[1]

转录信号传导子与激活子3在宫颈癌组织中的表达及临床意义 [J].

刘丽丽 ;

战雪梅 ;

孙崇伟 ;

孙莉莉 .

中华肿瘤防治杂志, 2007, (06) :447-449

[2]

塞来昔布对实验性结肠癌原位移植瘤生长及血管形成的影响 [J].

王磊 ;

陈卫昌 ;

谢学顺 ;

何扬 ;

白霞 .

中华肿瘤防治杂志, 2006, (17) :1295-1300

[3]

STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice [J].

Ernst, Matthias ;

Najdovska, Meri ;

Grail, Dianne ;

Lundgren-May, Therese ;

Buchert, Michael ;

Tye, Hazel ;

Matthews, Vance B. ;

Armes, Jane ;

Bhathal, Prithi S. ;

Hughes, Norman R. ;

Marcusson, Eric G. ;

Karras, James G. ;

Na, Songqing ;

Sedgwick, Jonathon D. ;

Hertzog, Paul J. ;

Jenkins, Brendan J. .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (05) :1727-1738

[4]

Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction [J].

Tsareva, Svetlana A. ;

Moriggl, Richard ;

Corvinus, Florian M. ;

Wiederanders, Bernd ;

Schuetz, Alexander ;

Kovacic, Boris ;

Friedrich, Karlheinz .

NEOPLASIA, 2007, 9 (04) :279-291

[5]

Activation of STAT3 is a marker of poor prognosis in human colorectal cancer [J].

Kusaba, Takafumi ;

Nakayama, Toshiyuki ;

Yamazumi, Kazuyuki ;

Yakata, Yuichi ;

Yoshizaki, Ayumi ;

Inoue, Kenichiro ;

Nagayasu, Takeshi ;

Sekine, Ichiro .

ONCOLOGY REPORTS, 2006, 15 (06) :1445-1451

[6]

Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth [J].

Corvinus, FM ;

Orth, C ;

Moriggl, R ;

Tsareva, SA ;

Wagner, S ;

Pfitzner, EB ;

Baus, D ;

Kaufmann, R ;

Huber, LA ;

Zatloukal, K ;

Beug, H ;

Öhlschäger, P ;

Schütz, A ;

Halbhuber, KJ ;

Friedrich, K .

NEOPLASIA, 2005, 7 (06) :545-555

[7]

Treatment of Crohn’s disease with anti-IL-6 receptor antibody.[J].Hiroaki Ito.Journal of Gastroenterology.2005, 16

[8]

TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling [J].

Becker, C ;

Fantini, MC ;

Schramm, C ;

Lehr, HA ;

Wirtz, S ;

Nikolaev, A ;

Burg, J ;

Strand, S ;

Kiesslich, R ;

Huber, S ;

Ito, H ;

Nishimoto, N ;

Yoshizaki, K ;

Nishimoto, N ;

Galle, PR ;

Blessing, M ;

Rose-John, S ;

Neurath, MF .

IMMUNITY, 2004, 21 (04) :491-501

[9]

Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis [J].

Alonzi, T ;

Newton, IP ;

Bryce, PJ ;

Di Carlo, E ;

Lattanzio, G ;

Tripodi, M ;

Musiani, P ;

Poli, V .

CYTOKINE, 2004, 26 (02) :45-56

[10]

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease [J].

Ito, H ;

Takazoe, M ;

Fukuda, Y ;

Hibi, T ;

Kusugami, K ;

Andoh, A ;

Matsumoto, T ;

Yamamura, T ;

Azuma, J ;

Nishimoto, N ;

Yoshizaki, K ;

Shimoyama, T ;

Kishimoto, T .

GASTROENTEROLOGY, 2004, 126 (04) :989-996

← 1 2 →